<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/q-biomed-otcmktsqbio-lifted-to-buy-at-zacks-investment-research.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T15:52:44+00:00"/>
    <meta property="og:title" content="Q BioMed (OTCMKTS:QBIO) Lifted to Buy at Zacks Investment Research"/>
    <meta property="og:description" content="Zacks Investment Research upgraded shares of Q BioMed (OTCMKTS:QBIO) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. They currently have $0.50 target price on the stock. According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, […]"/>
  </head>
  <body>
    <article>
      <h1>Q BioMed (OTCMKTS:QBIO) Lifted to Buy at Zacks Investment Research</h1>
      <address><time datetime="2019-11-18T15:52:44+00:00">18 Nov 2019, 15:52</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p><a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> upgraded shares of Q BioMed (OTCMKTS:QBIO) from a hold rating to a buy rating in a research report sent to investors on Friday morning, <a href="https://www.zacks.com//">Zacks.com</a> reports. They currently have $0.50 target price on the stock.</p>
      <p>According to Zacks, “Q BioMed Inc. is a biomedical acceleration and development company. It focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Q BioMed Inc. is based in New York. “</p>
      <p>Separately, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=QBIO">ValuEngine</a> upgraded shares of Q BioMed from a hold rating to a buy rating in a research note on Thursday, August 1st.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/OTCMKTS/QBIO/price-target/">Q BioMed stock</a> traded up $0.04 on Friday, reaching $0.43. The company had a trading volume of 131,446 shares, compared to its average volume of 60,362. The firm has a market cap of $6.50 million, a price-to-earnings ratio of -0.64 and a beta of 3.85. Q BioMed has a 1 year low of $0.34 and a 1 year high of $2.54. The firm’s 50-day moving average price is $0.46 and its two-hundred day moving average price is $1.08.</p>
      <p>Q BioMed (OTCMKTS:QBIO) last announced its quarterly earnings results on Tuesday, October 15th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.05). Equities analysts expect that Q BioMed will post -0.64 EPS for the current fiscal year.</p>
      <p>
        <b>Q BioMed Company Profile</b>
      </p>
      <p>Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer.</p>
      <p>Read More: <a href="https://www.marketbeat.com/financial-terms/difference-between-common-shares-and-convertible-shares/">Convertible Shares</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=QBIO">Get a free copy of the Zacks research report on Q BioMed (QBIO)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
    </article>
  </body>
</html>